BrainsWay (ADR) Logo
US10501L1061
A2PCBP
BWAY

BrainsWay (ADR)

Kurser indlæses...

Prognose

Analytikernes gennemsnitlige kursmål er 17,73 € (+108,34 %). Medianen er 17,73 € (+108,34 %).

Køb
  7
Behold
  1
Sælg
  0

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • BrainsWay beats revenue forecasts in Q2 2026 and raises full-year outlook

    BrainsWay reported revenue of $17.1 million in Q2 2026, beating analysts’ estimate of $16.31 million; adjusted earnings per share were $0.07, in line with expectations. The company raised its 2026 revenue guidance to $68–70 million and recorded revenue growth of 35% year over year along with more than a fourfold increase in operating income. Gross margin remained steady at 75%, adjusted EBITDA was positive for the twelfth consecutive quarter, and the installed system base rose to around 1,950 units. Management cites strong demand for Deep TMS and the SWIFT protocol, as well as reimbursements covering about 57 million insured people, as drivers. » Mere på de.investing.com


  • BrainsWay invests $3 million in Radial Health

    BrainsWay has acquired a $3 million minority stake in Radial Health as part of a Series A financing round. Radial operates a network of brain-medicine clinics and develops clinical infrastructure, reimbursement tools, and an AI-supported decision platform for non-invasive therapies such as Deep TMS. The capital will be used to expand clinical presence, strengthen the technology platform and evaluate M&A opportunities; BrainsWay describes the investment as part of a strategy to acquire minority stakes in mental health care providers. » Mere på de.investing.com


  • BrainsWay: US insurers allow psychiatric nurse practitioners to provide TMS treatment

    A growing number of US insurers, including Optum/United Behavioral Health, have allowed psychiatric nurse practitioners in full-practice states since the end of 2025 to prescribe, supervise and administer transcranial magnetic stimulation (TMS) for commercial plans covering about 34.8 million enrollees. Other payers and providers such as First Coast, National Government Services, Novitas, the VA and TRICARE West have introduced similar reimbursement models, subject to regulatory requirements. BrainsWay sees this as an opportunity to improve access to deep TMS and shorten waiting times; the stock reacted positively and is trading near its 52-week high after a 258% gain last year. » Mere på de.investing.com


  • BrainsWay invests additional $6 million in Neurolief after FDA premarket clearance

    BrainsWay closes a milestone-based convertible note of $6 million as a second tranche for Neurolief after Neurolief received FDA premarket clearance for the Proliv™Rx system. With this, BrainsWay has invested a total of $11 million in Neurolief; a third tranche of up to $5 million is possible if a revenue-based target is met. BrainsWay also holds a purchase option on all outstanding shares of Neurolief, with the price tied to a fixed company valuation or a revenue multiple. Parallel to the financing, Neurolief is expanding provider access by adding an authorized distributor to the U.S. Department of Veterans Affairs supplier list. » Mere på de.investing.com


  • BrainsWay: Highmark plans expanded reimbursement for accelerated Deep‑TMS protocol

    Highmark Blue Cross Blue Shield has issued a draft policy to expand reimbursement for BrainsWay’s accelerated SWIFT‑Deep‑TMS protocol for adolescents and adults with major depressive disorder. After a public comment period, the rule is expected to take effect in February 2026 and covers a five‑times‑daily, 10‑minute program over six days plus follow‑up sessions (38 sessions in total). The FDA approved the protocol in September 2025; data showed a response rate of 87.8% and a remission rate of 78.0%, prompting BrainsWay to anticipate broader market acceptance. » Mere på de.investing.com

Virksomhedstal

I det seneste kvartal havde BrainsWay (ADR) en omsætning på 15,89 mio. € og et nettoresultat på 1,95 mio. €
(EUR) september 2026
YoY
Omsætning 15,89 mio. 37,99 %
Bruttofortjeneste 12,38 mio. 42,96 %
Nettoresultat 1,95 mio. 45,79 %
EBITDA 2,68 mio. 13,12 %

Fundamentale data

Nøgletal Værdi
Markedsværdi
360,6 mio. €
Antal aktier
39,22 mio.
Højeste/laveste i 52 uger
15,82 € - 4,58 €
Udbytte Nej
Beta
0,15
P/E (PE Ratio)
38,94
PEG (PEG Ratio)
0,62
K/I (PB Ratio)
4,90
P/S (PS Ratio)
5,83

Virksomhedsprofil

Brainsway Ltd. udvikler og sælger non-invasive neurostimulationsbehandlinger til psykiske lidelser i USA, Europa, Israel og internationalt. Selskabet tilbyder Deep Transcranial Magnetic Stimulation-platformsteknologi til behandling af svær depression, angstdepression, tvangslidelser (OCD), rygeafhængighed, bipolar lidelse, posttraumatisk stresslidelse, skizofreni, Alzheimers sygdom, autisme, kronisk smerte, multipel sklerose, genoptræning efter apopleksi og Parkinsons sygdom. Selskabet betjener primært læger, hospitaler og medicinske centre inden for psykiatrien. Brainsway Ltd. blev grundlagt i 2003 og har hovedsæde i Jerusalem, Israel.

Navn
BrainsWay (ADR)
CEO
Hadar Levy
Hjemsted Jerusalem, jm
Israel
Websted
Sektor
Sundhed
Branche
Sundhedsudstyr og -produkter
Børsnotering
17.12.2018
Medarbejdere 129

Tickersymboler

Børs Symbol
NASDAQ
BWAY
🍪

Parqet  bruger cookies. Læs mere